Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

With the rising popularity of glucagon-like peptide-1 agents for treating obesity, many bariatric surgery programs across the ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

GLP-1 RAs are known to delay gastric emptying, raising concerns about regurgitation, aspiration, and airway compromise during ...

Most patients do not need to pause their GLP-1 medications prior to elective surgery, according to updated guidance from several medical societies, including the American Society of Anesthesiologists, ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

A new guideline released on World Diabetes Day will give GPs and other health professionals positive recommendations for optimal diabetes management ...

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon-like peptide-1 receptor agonists (GLP-1 ...

In obesity and diabetes, the leading GLP-1 drugs, which include Novo’s Wegovy and Ozempic, require injections once a week.

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...